Hey, lay off Percy. I don't agree with his call, but it is his to make. I held GNTA, hoping it would do half as well as Imclone after they had their first FDA rejection. Then their partner announced it was bailing out. GNTA could still get an approval, it doesn't take much improvement in certain cancers to get an approval. But they need to get Genasense approved, and it is a first generation antisense drug. Less effectiveness, more side effects. It attacks a nice target though. Take their target with the AVII third generation chemistry and you'd have a good drug. As for selling CYGX, I just disagree. We are entitled to disagree on this board, without getting attacked for it. CYGX might be an OTC stock, but it won't be for long, in my opinion. Mark my words, we will be over $5.00 a share by Dec 31, 2005. GNTA probably won't, and if they don't get another partner, they will be out of business by then. AVII and ISIS are both better antisense plays than GNTA. ISIS has a much deeper pipeline, future royalties for Macugen, the TIGER biosensor system. AVII has management with ADD, but great science. Anyway, all this is of course just my opinion. No one knows the future,or if they do, they are not letting the rest of us in on it.
Best wishes to all for 2005. I have a feeling it is going to be a trmendous year for us CYGX longs!
News 
Market Data 
Discover 
AI
